Analysis
Customs
1 min read
US Tariffs May Disrupt Indian CDMOs Through Innovator Company Pressure
Full Story
The U.S. imposed tariffs up to 100% on patented pharmaceutical imports, creating uncertainty for Indian CDMOs.
Background
President Trump's move aims to pressure pharma companies to manufacture in the U.S., citing national security and supply chain risks. Generics, comprising 90% of Indian pharma exports to the U.S., are currently exempt.
Key Analysis
Innovator pressure
Innovators may move production to the U.S..
Selective impact
Firms with patented product exposure face challenges.
Generics review
A review may extend tariffs to generics.
Bottom Line
Indian CDMOs face potential disruptions and must monitor policy changes.
Watch For
Monitor the U.S. Commerce Department's year-long review outcomes.
Related Articles
12 Apr 2026
· Customs
India-UK Free Trade Agreement May Begin in Second Week of May
11 Apr 2026
· Customs
Minimum Export Price for Natural Honey Extended
10 Apr 2026
· Customs
Mumbai Customs Seizes INR 38 Crore Worth of Gold from 24 Women
09 Apr 2026
· Customs
Customs Duty and AIDC Exemptions Granted for Specific Imports
09 Apr 2026
· Customs